Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma

被引:12
|
作者
Kanai, Tomoya [1 ]
Ito, Zensho [1 ]
Oji, Yusuke [2 ]
Suka, Machi [3 ]
Nishida, Sumiyuki [4 ]
Takakura, Kazuki [1 ]
Kajihara, Mikio [1 ]
Saruta, Masayuki [5 ]
Fujioka, Shuichi [6 ]
Misawa, Takeyuki [6 ]
Akiba, Tadashi [6 ]
Yanagisawa, Hiroyuki [3 ]
Shimodaira, Shigetaka [7 ]
Okamoto, Masato [8 ]
Sugiyama, Haruo [9 ]
Koido, Shigeo [1 ,10 ]
机构
[1] Jikei Univ, Sch Med, Kashiwa Hosp, Div Gastroenterol & Hepatol,Dept Internal Med, 163-1 Kashiwa Shita, Kashiwa, Chiba 2778567, Japan
[2] Osaka Univ, Grad Sch Med, Dept Funct Diagnost Sci, Suita, Osaka 5650871, Japan
[3] Jikei Univ, Sch Med, Dept Publ Hlth & Environm Med, Tokyo 1058571, Japan
[4] Osaka Univ, Grad Sch Med, Dept Resp Med & Clin Immunol, Suita, Osaka 5650871, Japan
[5] Jikei Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo 1058571, Japan
[6] Jikei Univ, Sch Med, Kashiwa Hosp, Dept Surg, Kashiwa, Chiba 2778567, Japan
[7] Kanazawa Med Univ, Dept Regenerat Med, Uchinada, Ishikawa 9200293, Japan
[8] Osaka Univ, Grad Sch Med, Dept Adv Immunotherapeut, Suita, Osaka 5650871, Japan
[9] Osaka Univ, Grad Sch Med, Dept Canc Immunol, Suita, Osaka 5650871, Japan
[10] Jikei Univ, Sch Med, Inst Clin Med & Res, Kashiwa, Chiba 2778567, Japan
关键词
Wilms' tumor 1; pancreatic cancer; prognosis; GENE WT1; 5-YEAR SURVIVORS; POOR-PROGNOSIS; CANCER-CELLS; PROTEIN; GEMCITABINE; THERAPY; OVEREXPRESSION; CARCINOMA; LEUKEMIA;
D O I
10.3892/ol.2018.8961
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The only current curative treatment for patients with pancreatic ductal adenocarcinoma (PDA) is surgical resection, and certain patients still succumb to disease shortly after complete surgical resection. Wilms' tumor 1 (WT1) serves an oncogenic role in various types of tumors; therefore, in the present study, WT1 protein expression in patients with PDA was analyzed and the association with overall survival (OS) and disease-free survival (DFS) time in patients with PDA was assessed following surgical resection. A total of 50 consecutive patients with PDA who received surgical resection between January 2005 and December 2015 at the Jikei University Kashiwa Hospital (Kashiwa, Chiba, Japan) were enrolled. WT1 protein expression in PDA tissue was measured using immunohistochemical staining. Furthermore, laboratory parameters were measured within 2 weeks of surgery, and systemic inflammatory response markers were evaluated. WT1 protein expression was detected in the nucleus and cytoplasm of all PDA cells and in tumor vessels. WT1 exhibited weak staining in the nuclei of all PDA cells; however, the cytoplasmic expression of WT1 levels was classified into four groups: Negative (n=0), weak (n=19), moderate (n=23) and strong (n=8). In patients with PDA, it was demonstrated that the OS and DFS times of patients with weak cytoplasmic WT1 expression were significantly prolonged compared with those of patients with moderate-to-strong cytoplasmic WT1 expression, as determined by log-rank test (P=0.0005 and P=0.0001, respectively). Furthermore, an association between the density of WT1-expressing tumor vessels and worse OS/DFS times was detected. Multivariate analysis also indicated a significant association between the overexpression of WT1 in PDA tissue and worse OS/DFS times. To the best of our knowledge, the present study is the first to demonstrate that moderate-to-strong overexpression of WT1 in the cytoplasm of PDA cells is significantly associated with worse OS/DFS times. Therefore, overexpression of WT1 in the cytoplasm of PDA cells may impact the recurrence and prognosis of patients with PDA following surgical resection. The results further support the development of WT1-targeted therapies to prolong survival in all patients with PDA.
引用
收藏
页码:2682 / 2692
页数:11
相关论文
共 50 条
  • [41] Prognostic Significance of 18F-FDG PET/CT and Tumor Metabolic Changes in Patients With Pancreatic Ductal Adenocarcinoma
    Shimomura, Ayaka
    Oshima, Minoru
    Suto, Hironobu
    Matsukawa, Hiroyuki
    Kondo, Akihiro
    Ando, Yasuhisa
    Kishino, Takayoshi
    Kumamoto, Kensuke
    Sato, Kiyotoshi
    Sugimoto, Masahiro
    Nagao, Mina
    Miyatake, Nobuyuki
    Norikane, Takashi
    Soga, Tomoyoshi
    Okano, Keiichi
    ANTICANCER RESEARCH, 2024, 44 (08) : 3321 - 3330
  • [42] CDX2 and SATB2 in Pancreatic Ductal Adenocarcinoma: Expression and Prognostic Significance
    Bsirini, Caroline
    Chen, Irene
    Ettel, Mark
    Bell, Phoenix
    Findeis-Hosey, Jennifer
    Dunne, Richard
    Drage, Michael
    Agostini-Vulaj, Diana
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1034 - 1035
  • [43] Expression of LRP16 in pancreatic ductal adenocarcinoma and its clinicopathological significance and prognostic value
    Huang, Yong
    An, Xiaojing
    Zhao, Po
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (06): : 6918 - 6923
  • [44] CDX2 and SATB2 in Pancreatic Ductal Adenocarcinoma: Expression and Prognostic Significance
    Bsirini, Caroline
    Chen, Irene
    Ettel, Mark
    Bell, Phoenix
    Findeis-Hosey, Jennifer
    Dunne, Richard
    Drage, Michael
    Agostini-Vulaj, Diana
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1034 - 1035
  • [45] Expression of microRNA-200c in human pancreatic ductal adenocarcinoma and its prognostic significance
    Liu, Jun-Ping
    Shang, Jia
    Kang, Yi
    Mao, Chong-Shan
    Ning, Hui-Bin
    Ma, Chao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (09): : 9455 - 9460
  • [46] Expression and clinical significance of placenta-specific 1 in pancreatic ductal adenocarcinoma
    Yin, Yin
    Zhu, Xu
    Huang, Shanshan
    Zheng, Jiawei
    Zhang, Mengyun
    Kong, Wencui
    Chen, Qun
    Zhang, Yan
    Chen, Xiong
    Lin, Kerong
    Ouyang, Xuenong
    TUMOR BIOLOGY, 2017, 39 (06)
  • [47] USPs in Pancreatic Ductal Adenocarcinoma: A Comprehensive Bioinformatic Analysis of Expression, Prognostic Significance, and Immune Infiltration
    Wang, Yizhi
    Zhou, Dongkai
    Kong, Yang
    Yang, Qifan
    Ding, Yuan
    Wang, Weilin
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [48] Gli1 expression in pancreatic ductal adenocarcinoma and its clinical significance
    Abula, Y.
    Yi, C.
    Wang, X. -Y.
    Wang, M.
    Qin, R. -Y.
    Guo, Y. -Q.
    Lin, H.
    Li, H. -J.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04) : 12323 - 12329
  • [49] Clinical Significance of Phosphorylated Sphingosine Kinase 1 Expression in Pancreatic Ductal Adenocarcinoma
    Nagaro, Hiroki
    Ichikawa, Hiroshi
    Takizawa, Kazuyasu
    Nagahashi, Masayuki
    Abe, Shun
    Hirose, Yuki
    Moro, Kazuki
    Miura, Kohei
    Nakano, Masato
    Shimada, Yoshifumi
    Sakata, Jun
    Wakai, Toshifumi
    ANTICANCER RESEARCH, 2023, 43 (09) : 3969 - 3977
  • [50] Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma
    Giaginis, Constantinos
    Davides, Demetrios
    Zarros, Apostolos
    Noussia, Olga
    Zizi-Serbetzoglou, Adamantia
    Kouraklis, Gregorios
    Theocharis, Stamatios
    DIGESTIVE DISEASES AND SCIENCES, 2008, 53 (06) : 1728 - 1734